01.06.2023 - By PeerVoice
Visit https://www.peervoice.com/VHW860 to view the entire programme with slides. After completing “Frederique Penault-Llorca, MD, PhD - Setting Our Sights on Actionable Mutations in Cholangiocarcinoma: The Who, What, When, Why, and How of Testing”, participants will be able to: Recognise the value of molecular testing for patients with cholangiocarcinoma (CCA) in order to identify candidates for targeted therapies; Describe advantages and disadvantages to available molecular testing methods for CCA; and Evaluate the optimal timing for molecular testing in patients with CCA to inform treatment plans.